Zai Lab Reports Q2 2026 Revenue of $106.3 Million
Zai Lab reported total revenues of $106.3 million in Q2 2026, achieving sequential growth driven by ZEJULA and VYVGART. The company highlighted multiple clinical pipeline advancements and confirmed momentum for potential regulatory filings next year.
View filing at SEC.gov →